NCT04563702View on ClinicalTrials.gov

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

October 10, 2021

Study Completion Date

October 10, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

VXA-CoV2-1

non replicating Ad5 adjuvanted oral tableted vaccine

Trial Locations (1)

90630

WCCT, Cypress

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT04563702 - Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects | Biotech Hunter | Biotech Hunter